Is ipamorelin FDA-approved in 2026? Learn about its FDA status, 503A and 503B compounding restrictions, clinical trial findings, safety concerns, and WADA rules.
Key Takeaways
Ipamorelin is not FDA-approved for any medical indication as of October 2026.
Its clinical development included a Phase 2 program investigating postoperative ileus, but the main efficacy endpoint was not statistically significant.
FDA lists ipamorelin acetate in Category 2 under its interim 503B compounding policy, citing potential safety concerns and insufficient information about certain routes of administration.
An FDA advisory committee voted against adding ipamorelin free base and ipamorelin acetate to the Section 503A Bulks List in October 2024.
Withdrawal of a nomination does not mean FDA approved ipamorelin or authorized routine compounding.
Evidence from clinical research does not establish ipamorelin as an effective treatment for weight loss, muscle gain, anti-aging, or growth hormone deficiency.
Ipamorelin is included in the 2026 World Anti-Doping Agency (WADA) Prohibited List.
Is Ipamorelin FDA-Approved in 2026?
No. As of October 23, 2026, ipamorelin is not FDA-approved for any human medical indication.
There is no FDA-approved ipamorelin drug product or approved prescribing label for treating a medical condition. Its investigational history does not amount to regulatory approval, and products marketed as ipamorelin should not be confused with medicines that have completed FDA’s drug-approval process.
Ipamorelin is a synthetic peptide studied for its effects on the ghrelin receptor and growth hormone release. Interest in these biological effects has led to research into several possible applications, but scientific interest and commercial availability do not establish that a compound is safe and effective for human treatment.
It is also important to separate three different regulatory questions:
FDA drug approval: Has FDA approved a specific drug product for a particular indication?
Compounding eligibility: Does a bulk substance meet the legal requirements that apply to a particular type of compounding?
Research evidence: What have laboratory, animal, and human studies actually demonstrated?
A substance can have published studies without being an approved medicine. Likewise, a change in compounding policy does not automatically confer FDA drug approval.
Ipamorelin FDA Status: Regulatory Overview
Regulatory question | Status in October 2026 |
Is ipamorelin FDA-approved? | No |
Does it have an FDA-approved therapeutic indication? | No |
Is ipamorelin acetate listed in FDA’s 503B Category 2? | Yes, under the agency’s interim policy |
Was ipamorelin recommended for inclusion on the 503A Bulks List in October 2024? | No; the advisory committee voted against inclusion |
Does withdrawal of a nomination constitute approval? | No |
Is it included on WADA’s 2026 Prohibited List? | Yes |
FDA’s official compounding pages and advisory committee records are the primary sources for checking the regulatory position. The current 503A and 503B rules should be considered separately because they apply to different compounding settings.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide, meaning it contains five amino-acid residues. It belongs to the growth hormone-releasing peptide (GHRP) class and has been studied as an agonist of the growth hormone secretagogue receptor type 1a, commonly called the ghrelin receptor.
Researchers have investigated ipamorelin because receptor activation can stimulate the release of growth hormone. However, a biological effect observed in a study does not establish a clinical benefit for a particular condition.
The key scientific distinction is between demonstrating a mechanism and demonstrating a treatment effect. The first can help explain how a compound acts; the second requires appropriate clinical evidence showing that the compound improves meaningful outcomes with acceptable safety.
How Does Ipamorelin Work?
Ipamorelin has been studied for its activity at the growth hormone secretagogue receptor, or GHS-R1a. This receptor is involved in signaling associated with ghrelin and the regulation of growth hormone release.
Its mechanism is different from that of tesamorelin, an FDA-approved growth hormone-releasing hormone (GHRH) analog marketed as Egrifta for a specific indication related to excess abdominal fat in adults with HIV-associated lipodystrophy.
Feature | Ipamorelin | Tesamorelin |
Drug class | Growth hormone-releasing peptide | GHRH analog |
Main receptor pathway | GHS-R1a, the ghrelin receptor | GHRH receptor |
FDA-approved drug product | No | Yes, for specific labeled indications |
Regulatory status | Not FDA-approved | FDA-approved for its labeled use |
Does one substitute for the other? | No | No |
The comparison illustrates why compounds that affect the same broad hormonal system should not be treated as equivalent medicines. They differ in molecular structure, receptor activity, clinical evidence, and regulatory status.
For current prescribing details and approved indications, consult FDA’s official drug information rather than relying on comparisons in promotional material.
What Does Clinical Research Show?
One of the most relevant clinical development programs investigated ipamorelin for postoperative ileus, a temporary disruption of normal gastrointestinal movement that can occur after surgery.
A Phase 2 randomized, placebo-controlled study evaluated ipamorelin in patients recovering from bowel resection. The primary outcome included the time until patients could tolerate a standardized solid meal. Although the study reported a numerical difference between treatment and placebo groups, the difference was not statistically significant.
The findings therefore did not establish that ipamorelin was effective for the primary outcome. The clinical development program did not result in an FDA-approved medicine.
This history is important because claims about ipamorelin often focus on growth hormone release rather than the outcomes actually evaluated in human trials.
What the evidence does—and does not—show
The existing clinical record does not establish ipamorelin as an effective treatment for:
Weight loss or fat reduction
Muscle growth or athletic performance
Anti-aging or longevity
Improved sleep or skin appearance
Growth hormone deficiency
These are distinct medical or performance-related claims. Evidence related to one biological pathway or clinical setting cannot automatically be used to support all of them.
A useful way to assess any claim is to ask: Was ipamorelin itself studied in humans, what outcome was measured, and did the study demonstrate a clinically meaningful benefit?
Why Is Ipamorelin Not FDA-Approved?
FDA approval requires evidence that a specific drug product meets the applicable standards for safety and effectiveness for its proposed use, along with adequate manufacturing and quality information.
Ipamorelin has been investigated clinically, but its research history has not resulted in an approved drug product. The Phase 2 postoperative ileus program did not establish a statistically significant benefit on its primary endpoint, and clinical development did not progress to an FDA-approved treatment.
It would be speculative to attribute the absence of approval to a single commercial, patent, or sponsorship factor without reliable supporting evidence. The more important point for readers is that ipamorelin has not completed the process required for FDA drug approval.
Ipamorelin Compounding Status: 503A vs. 503B
FDA approval and compounding eligibility are separate regulatory questions. Ipamorelin’s compounding history has included an advisory committee review and an FDA safety-risk listing.
Section 503A: Pharmacy compounding
Section 503A applies to certain compounding by state-licensed pharmacists and physicians. Under the statute, bulk drug substances must meet applicable requirements, which can include a relevant USP or National Formulary monograph, being a component of an FDA-approved drug product, or appearing on FDA’s 503A Bulks List when the other statutory conditions apply.
In October 2024, FDA’s Pharmacy Compounding Advisory Committee considered ipamorelin free base and ipamorelin acetate for possible inclusion on the 503A Bulks List. The committee voted against inclusion, with the vote reported as 0–12 and one abstention.
The nominations were subsequently withdrawn. FDA had nevertheless continued its evaluation at that meeting. A withdrawn nomination is not the same as a favorable FDA decision, and the advisory committee vote did not approve ipamorelin as a drug.
As of this article’s October 2026 update, ipamorelin should not be described as being on the 503A Bulks List without confirmation from a subsequent official FDA determination.
Section 503B: Outsourcing facilities
FDA lists ipamorelin acetate in Category 2 under its interim 503B compounding policy, with a date of September 29, 2023.
Category 2 identifies bulk drug substances for which FDA has identified potential significant safety risks and does not extend the more permissive interim enforcement policy that may apply to certain Category 1 substances.
FDA’s stated concerns about ipamorelin acetate include:
Potential immunogenicity associated with peptide aggregation or peptide-related impurities for certain routes of administration
The added complexity of characterizing the peptide because it contains unnatural amino acids
Reports of serious adverse events, including a death, in a study involving intravenous ipamorelin for gastric motility
Insufficient safety information to determine the risks associated with certain other injectable routes
These statements describe FDA’s concerns and information gaps. They should not be misrepresented as proof that every possible route has the same risk profile—or as evidence that other routes are safe.
Compounding status at a glance
Question | What the regulatory record indicates |
Does 503A eligibility mean FDA approval? | No |
Did the October 2024 committee vote support adding ipamorelin to the 503A Bulks List? | No |
Is ipamorelin acetate listed in 503B Category 2? | Yes, under FDA’s interim policy |
Does Category 2 status establish that a substance is safe to compound? | No |
Can a nomination withdrawal be described as FDA authorization? | No |
Because compounding policies and formal listings can change, verify the latest FDA pages before publishing a claim about current eligibility.
What Safety Concerns Has FDA Identified?
FDA’s compounding safety information highlights potential issues with ipamorelin acetate, including immunogenicity, peptide aggregation, peptide-related impurities, and challenges in characterizing the active ingredient.
FDA also describes a report of serious adverse events, including a death, in a study involving intravenous administration for gastric motility. The agency has stated that it lacks sufficient information to determine whether ipamorelin acetate could cause harm through certain other injectable routes.
The significance of these concerns is straightforward: available information does not establish a comprehensive safety profile for all formulations and routes of administration.
Products sold online may also differ in identity, purity, sterility, and manufacturing quality. A product label, “research grade” description, or certificate of analysis does not establish FDA approval or prove that a product is suitable for human use.
Is Ipamorelin Banned by WADA?
Yes. Ipamorelin appears in the 2026 World Anti-Doping Agency Prohibited List under the category covering growth hormone-releasing peptides and related substances. The relevant category, S2, is prohibited at all times—both in and out of competition.
WADA’s rules and FDA’s approval process serve different purposes. A substance can be prohibited in sport without being an FDA-approved medicine.
Athletes subject to anti-doping rules should consult the current official WADA list and their applicable anti-doping organization for authoritative guidance.
Frequently Asked Questions
Is ipamorelin FDA-approved in 2026?
No. As of October 2026, ipamorelin is not FDA-approved for any human medical indication.
Has ipamorelin ever been studied in humans?
Yes. Clinical research has included a Phase 2 program investigating ipamorelin for postoperative ileus. The study did not demonstrate a statistically significant benefit on its primary efficacy endpoint.
Can ipamorelin be described as FDA-approved because it is compounded?
No. Compounding eligibility and FDA drug approval are separate regulatory matters. A compounded product is not automatically FDA-approved, and a bulk substance must meet the applicable legal requirements for the relevant compounding pathway.
What is the difference between 503A and 503B?
Section 503A generally concerns compounding by state-licensed pharmacists and physicians under specified conditions. Section 503B concerns registered outsourcing facilities and has a separate regulatory framework. A substance’s status under one section does not automatically establish eligibility under the other.
Why is ipamorelin acetate in FDA Category 2?
FDA has identified potential safety concerns involving immunogenicity, aggregation, peptide-related impurities, and the complexity of characterizing the substance. The agency also cited serious adverse events reported with intravenous use and a lack of sufficient safety information for certain other injectable routes.
Is ipamorelin effective for weight loss or muscle gain?
Current clinical evidence does not establish ipamorelin as an effective treatment for weight loss, muscle gain, or anti-aging. Findings about growth hormone release alone do not prove these outcomes.
Is ipamorelin the same as tesamorelin?
No. Ipamorelin acts through the ghrelin receptor and is not FDA-approved. Tesamorelin is a GHRH analog with FDA-approved drug products for specific labeled indications. They are not interchangeable medicines.
Is ipamorelin prohibited in sports?
Yes. Ipamorelin is included in the 2026 WADA Prohibited List under the growth hormone-releasing peptide category. Consult the current official list for the applicable rules.
Where can I check the latest ipamorelin FDA status?
Consult FDA’s official compounding pages, the October 2024 Pharmacy Compounding Advisory Committee meeting materials, and FDA’s drug approval information. For anti-doping status, consult WADA’s current Prohibited List.
Conclusion: What Is Ipamorelin’s FDA Status in 2026?
As of October 23, 2026, ipamorelin is not FDA-approved for any medical indication.
Its clinical research history includes a Phase 2 study of postoperative ileus that did not meet its primary efficacy endpoint at statistical significance. FDA has also identified safety-information gaps and potential risks related to ipamorelin acetate in the context of compounding.
The October 2024 advisory committee vote did not support adding ipamorelin free base or acetate to the 503A Bulks List. Separately, ipamorelin acetate remains listed in Category 2 under FDA’s interim 503B compounding policy. Neither status should be confused with approval of a finished drug product.
For accurate reporting, keep three questions separate: whether a drug is FDA-approved, whether a substance meets the legal requirements for a particular compounding pathway, and what clinical research has demonstrated. Check official FDA and WADA records before publishing any later regulatory change.
Reference :
LiveNow Longevity — Is Ipamorelin FDA-Approved? Status in 2026: https://www.livenowlongevity.com/did-the-fda-approve-ipamorelin
Peptigrity — Is Ipamorelin FDA Approved? Legal Status, Prescription & WADA: https://peptigrity.com/blog/is-ipamorelin-fda-approved
Molecular Reference — Ipamorelin: gentle GH peptide for recovery & gains: https://molecularreference.com/peptides/ipamorelin
PeptideMethods — Ipamorelin Q2 2026: what changed: https://peptidemethods.com/blog/ipamorelin-q2-2026-quarterly-update
Superpower — Ipamorelin: How It Works, Evidence, and FDA Status: https://superpower.com/guides/peptides/ipamorelin
InCare — 9 Facts on Ipamorelin FDA Approval Status in 2026: https://www.incarenow.com/9-facts-on-ipamorelin-fda-approval-status-in-2026/
PeptideAgent — Current status of Ipamorelin in the United States: https://peptideagent.ai/regulatory/ipamorelin
Halftime Health — Ipamorelin Regulatory Status: Compounding Access in 2026: https://www.halftime.health/learning-center/ipamorelin-regulatory
Peptides Academy — Ipamorelin: a growth hormone secretagogue: https://peptidesacademy.co/peptides/ipamorelin
LiveNow Longevity — Peptide Regulatory Status Tracker (2026): https://www.livenowlongevity.com/peptide-regulatory-tracker
